Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis
Frontiers in Public Health · 2024
DOI: 10.3389/fpubh.2024.1421826 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, 2024. Verfasst von Hongfu Cai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Triple Negative Breast Neoplasms, Quality-Adjusted Life Years, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
This study focuses on assessing the cost-effectiveness of incorporating toripalimab alongside chemotherapy for the treatment of patients diagnosed with metastatic triple-negative breast cancer from the perspective of the Chinese healthcare system.
Methods
A partitioned survival model was constructed to simulate the costs and health outcomes over the lifetime of patients with mTNBC. Clinical data regarding overall survival, progression-free survival, and treatment-related adverse events were derived from the TORCHLIGHT clinical trials. Incremental cost-effectiveness ratio (ICER) were calculated based on the gains in quality-adjusted life-year (QALY). The willingness-to-pay (WTP) threshold was defined as $39,855.79 per QALY. Additionally, sensitivity analyses were conducted to examine the robustness of the model.
Results
The total cost incurred by the group receiving toripalimab was $38,040.62, while the placebo plus chemotherapy was $26,102.07. The utilization of the toripalimab regimen resulted in an increase of 0.74 QALYs and an incremental cost of $11,938.55 compared to the placebo plus chemotherapy group. The ICER was $16,133.18/QALY, indicating that toripalimab plus chemotherapy is a cost-effective strategy according to the WTP threshold. Sensitivity analyses confirmed the robustness of the results.
Conclusion
This study suggests that the addition of toripalimab to chemotherapy for the treatment of mTNBC is a cost-effective strategy. The findings provide valuable evidence to guide decision-making regarding treatment selection for patients with mTNBC in China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.
- Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China.
- Department of Pharmacy, Cancer Hospital of Shantou University Medical College, Shantou, China.
Zitieren
APA
Cai, H., Huang, L., & Zheng, Z. (2024). Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2024.1421826
Vancouver
Cai H, Huang L, Zheng Z. Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis. Frontiers in Public Health. 2024. doi:10.3389/fpubh.2024.1421826
BibTeX
@article{Cai2024,
author = {Cai, Hongfu and Huang, Lisheng and Zheng, Zhiwei},
title = {Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis},
journal = {Frontiers in Public Health},
year = {2024},
doi = {10.3389/fpubh.2024.1421826}
}
EUVIMED